HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China TCM (570.HK) - Latest Updates on Privatization and the Potential Merger with Taiji Group

Pre-IPO Ximalaya - The Potential Risks and the Outlook

Pre-IPO Belle Fashion Group - Performance Has Picked Up, but Not yet Reversed

Akeso Biopharma Placement (9926.HK) - Would Investors Be Willing to Take a Gamble?

Escalation of Israel-Hamas War - Here's How Investors Should Position Themselves in Dramatic Changes

Equity Capital Markets

<ul>
<li>The growth factor drug market is highly competitive. Many competing products have been on the market for many years with NRDL reimbursement coverage and also accumulated rich recognition from doctors/patients.</li>
<li>Even if Pro-101 is approved for market launch, B&amp;K may have to reduce its price largely and invest heavily in market education/promotion. B&amp;K’s commercialization capability still needs to be verified.</li>
<li>Valuation of B&amp;K would be lower than peers. It is hard for B&amp;K to receive expected valuation premium since its latest round of post investment valuation is already RMB3.3 billion.</li>
</ul>


The growth factor drug market is highly competitive. Many competing products have been on the market for many years with NRDL reimbursement coverage and also accumulated rich recognition from doctors/patients.
Even if Pro-101 is approved for market launch, B&amp;K may have to reduce its price largely and invest heavily in market education/promotion. B&amp;K’s commercialization capability still needs to be verified.
Valuation of B&amp;K would be lower than peers. It is hard for B&amp;K to receive expected valuation premium since its latest round of post investment valuation is already RMB3.3 billion.


Staidson (Beijing) Biopharmaceuticals (300204 CH)

Pre-IPO B&K Corporation - Valuation Performance Could Be Disappointing